Clinical Trial Update: Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating a two-week retreatment interval for neovascular age-related macular degeneration that is refractory to monthly afliberc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Tennessee Retina | Conditions: Neovascular Age-related Macular Degeneration | Phase 4 | Status: UNKNOWN